Skip to main content

Table 4 Simulated economic outcomes in the Diabetes Prevention Program intervention groups over a lifetime: Sensitivity analyses

From: The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study

Variable Lifestyle Intervention vs. Placebo Intervention Metformin Intervention vs. Placebo Intervention
  ∆ Cost, $ ∆ QALYa ∆ Cost/∆ QALY, $ ∆ Cost, $ ∆ QALYa ∆ Cost/∆ QALY,$
Base-case analysis 635 0.57 1,124 3,922 0.13 31,286
 Age 25–44 y −395 0.63 Cost-saving 2,574 0.27 9,573
 Age 45–54 y 489 0.63 781 4,024 0.13 30,013
 Age 55–64 y 1,807 0.53 3,409 4,413 0.07 64,904
 Age 65–74 y 2,617 0.39 6,646 4,119 0.02 173,593
 Age ≥ 75 y 2,508 0.21 11,700 3,255 0.01 273,207
Reduced costb -3,696 0.57 Cost-saving 220 0.13 1,755
20 % reduced effectiveness 1,417 0.46 3,102 4,084 0.11 38,145
50 % reduced effectiveness 2,371 0.30 7,886 4,307 0.80 52,562
Reduced costb and 20 % reduced effectiveness -2,181 0.41 Cost-saving 635 0.10 6,576
Reduced costb and 50 % reduced effectiveness -348 0.23 Cost-saving 1,198 0.06 20,994
  1. a QALY quality-adjusted life-year
  2. bAssumes that lifestyle intervention is implemented in a closed group of 10 patients and that metformin intervention is implemented with generic metformin